Healthy Q2; profitability guidance upgraded
01/08/24 -"Q2 profitability was above the street’s expectations. A decent performance across most of the segments was offset by a weaker showing from Genomics/NGS. While the 2024 sales guidance was impacted by ..."
Pages
66
Language
English
Published on
01/08/24
You may also be interested by these reports :
31/07/26
Amplifon’s Q2 profitability surpassed market expectations, driven by healthy top-line growth across all regions, particularly in EMEA, a key market. ...
31/07/26
Emeis’ HY26 confirms its positive trend on both operating and debt metrics. Occupancy rates caught the momentum, especially in France and Germany, ...
30/07/26
Dräger’s final Q2 26 results confirmed the preliminary figures released on 13 July. Margins accelerated in both divisions, alongside a meaningful ...
29/07/26
bioMerieux’s H1 profitability largely met expectations. Q2 sales growth was driven by increases across both segments, supported by its GO28 growth ...